Stay updated on Concurrent VRP-HER2 & Pembrolizumab in Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Concurrent VRP-HER2 & Pembrolizumab in Breast Cancer Clinical Trial page.

Latest updates to the Concurrent VRP-HER2 & Pembrolizumab in Breast Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedThe page now shows Revision: v3.4.3 instead of v3.4.2.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedRevision tag updated from v3.4.1 to v3.4.2 with no visible changes to study details or page layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check39 days agoChange DetectedA minor revision label changed from v3.4.0 to v3.4.1; no observable changes to core study content or page structure. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check47 days agoChange DetectedPage updates include a new Show glossary option and updated meta-data labels (Last Update Submitted that Met QC Criteria) and version text (Revision: v3.4.0), with some older labels (No FEAR Act data) removed or reformatted. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check61 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no substantive changes to trial content, eligibility criteria, or results are observable. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check83 days agoChange DetectedAdded a dedicated Locations section listing North Carolina (Durham) as a study site, clarifying where the trial is conducted.SummaryDifference0.2%

Stay in the know with updates to Concurrent VRP-HER2 & Pembrolizumab in Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Concurrent VRP-HER2 & Pembrolizumab in Breast Cancer Clinical Trial page.